Elyxium Wealth’s Takeda Pharmaceutical TAK Stock Holding History

Elyxium Wealth’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,118	Closed	-$17.4K	–	1149
2025 Q4	$17.4K	Buy	+1,118	New	+$16K	﹤0.01%	628

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Elyxium Wealth's TAK Position: Q1 2026 in Review

Elyxium Wealth sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 1,118 shares — an estimated $17.4K sold.

Elyxium Wealth first reported a position in TAK in Q4 2025 and held it in 1 quarter. The position peaked at $17.4K in Q4 2025. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Elyxium Wealth reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 1,118 Takeda Pharmaceutical shares in Q1 2026, an estimated $17.4K.
Elyxium Wealth first reported a position in Takeda Pharmaceutical in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's Takeda Pharmaceutical position peaked at $17.4K in Q4 2025.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.